Bioadaptives PR 09/24/19
BIOADAPTIVES,INCannounces TizHemp,anewHemp-productDivision
& appointment of new CFO
LasVegasNevada,September24,2019,(GLOBENEWSWIRE)--viaNEWMEDIAWIRE--Bioadaptives,Inc.(OTCBB:BDPT)announcedtheCompany’sformationofTisHemp,anewoperatingdivisiontoconcentrateeffortsonwellness-relatedhemp-basedproducts,andtheappointmentofMr.RonLambrechtastheCompany’snewChiefFinancialOfficer,reportingtotheCEO,President,andBoard,effective1October,2019.
Dr.Jacobs,DirectorandCEOsaid,“WeareverypleasedtobeorganizingourCompanytobecomeasignificantparticipantintherelatively-newandexplosivehempproductsindustry.OurnewHempProductsDivisionwillfocusitsattentiononthedevelopment,testing,production,anddistributionofhemp-basedhealthandwellnessproductsforhumanandanimal application.Wefully support the perceived health benefits of hemp,and,as such,believe this expansiontobe anaturalcomplementtoourCompany’scoreproductplans,andakeycontributortofuturebottom-lineperformanceoftheCompany.Initialproductspromotinghealthandwellness,includingtopicals,nutritionalpowderandtea,willbe availableforsalebeginningOctoberofthisyear.”
Mr.RobertEllis,Presidentstated,“Wearepleasedtoannouncetheadditionof Mr.RonLambrechtasournewChiefFinancialOfficer.Mr.LambrechtisaWesternMontanaCPA,andavery successful businessman.We look forwardtohis participationinthefinancialmanagementoftheCompanyasweexpand.”Forthepast25yearsMr.Lambrechthasoperatedafinancialservicesbusinessinadditiontofacilitatinganumberoftechnologyacquisitionsandjointventuretransactions.
About BioAdaptives,Inc.
BioAdaptives,Inc.isafully-reporting,publiccompanytradingontheOTCBulletinBoardunderthe symbolBDPT.The companyis engagedinresearch, development, andmarketing of science-based nutraceuticalproducts forhuman and animalconsumption.
SAFE HARBORACT
Forward-LookingStatements:Thisreleasecontainsstatementsthatconstituteforward-lookingstatementswithinthemeaningof Section27AoftheSecurities Act of 1933,as amended,and
Section21EoftheSecuritiesExchangeActof1934,asamended.Thesestatementsappearinanumberofplacesinthis releaseandincludeallstatements thatarenotstatementsofhistoricalfact regarding the intent, belief orcurrentexpectations of BioAdaptives, Inc.andits directors oritsofficerswithrespectto,amongotherthings:(i)financingplans;(ii)trendsaffectingitsfinancialconditionorresultsofoperations;(iii)growthstrategyandoperatingstrategy.Thewords"may,""would,""will,""expect,""estimate,""can,""believe,""potential"andsimilarexpressionsandvariationsthereofareintendedtoidentify forward-lookingstatements. Investorsarecautionedthatanysuchforward-lookingstatementsarenotguaranteesoffutureperformanceandinvolverisksanduncertainties,manyofwhicharebeyondBioAdaptives,Inc.'sabilitytocontrol,andactual resultsmay differmaterially from those projected inthe forward-looking statementsas aresultofvariousfactors.MoreinformationaboutthepotentialfactorsthatcouldaffectthebusinessandfinancialresultsisandwillbeincludedinBioAdaptives,Inc.'sfilingswiththeSecuritiesand Exchange Commission.
Ticker: OTCBB:BDPT/OTC:BDPT/OP: BDPT
###
MediaContact:RobertW.Ellis
President,BioAdaptives,Inc702-659-8829EXT703
Email:rwe@bioadaptives.com
SOURCE:BioAdaptives,Inc.